66,703 research outputs found
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: Focus on staphylococcus aureus
No full textStaphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and the most frequent invasive infection due to methicillin-resistant S. aureus (MRSA). Treatment is challenging, particularly for MRSA, because of limited treatment options. Telavancin is a bactericidal lipoglycopeptide antibiotic that is active against a range of clinically relevant gram-positive pathogens including MRSA. In experimental animal models of sepsis telavancin was shown to be more effective than vancomycin. In clinically evaluable patients enrolled in a pilot study of uncomplicated SAB, cure rates were 88% for telavancin and 89% for standard therapy. Among patients with infection due to only gram-positive pathogens enrolled in the 2 phase 3 studies of telavancin for treatment of hospital-acquired pneumonia, cure rates for those with bacteremic S. aureus pneumonia were 41% (9/22, telavancin) and 40% (10/25, vancomycin) with identical mortality rates. These data support further evaluation of telavancin in larger, prospective studies of SAB
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia
No full textIntroduction: Hospital-acquired pneumonia is a common infection, associated with substantial mortality. Despite the increasing prevalence of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), approved treatment options for this pathogen are limited. Areas covered: This article reviews the pharmacokinetics, dosing, preclinical studies and clinical efficacy, and safety of telavancin, with a particular focus on results from trials in nosocomial pneumonia. PubMed and Congress websites were searched for relevant articles published between 2003 and 2010. Expert opinion: Telavancin is a lipoglycopeptide antibiotic with rapid, bactericidal activity against MRSA, and may provide another option for the treatment of nosocomial pneumonia, owing to Gram-positive pathogens. © 2011 Informa UK, Ltd.American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P388, DOI DOI 10.1164-RCCM.200405-644ST; Andrews J, 2007, J ANTIMICROB CHEMOTH, V60, P677, DOI 10.1093-jac-dkm242; *AST PHARM INC, 2009, VIBATIV TEL INJ; Barcia-Macay M, 2008, J ANTIMICROB CHEMOTH, V61, P1288, DOI 10.1093-jac-dkn120; Barriere Steven, 2004, Journal of Clinical Pharmacology, V44, P689, DOI 10.1177-0091270004266620; Boselli E, 2005, CRIT CARE MED, V33, P1529, DOI 10.1097-01.CCM.0000168206.59873.80; Chang FY, 2003, MEDICINE, V82, P333, DOI 10.1097-01.md.0000091184.93122.09; Conte JE, 2002, ANTIMICROB AGENTS CH, V46, P1475, DOI 10.1128-AAC.46.5.1475-1480.2002; Corey GR, 2009, NAT REV DRUG DISCOV, V8, P929, DOI 10.1038-nrd3051; Corey GR, 2010, CLIN INFECT DIS, V51, P641, DOI 10.1086-655827; Cruciani M, 1996, J ANTIMICROB CHEMOTH, V38, P865; *CUB PHARM INC, 2010, CUB DAPT INJ PACK IN; Draghi DC, 2008, ANTIMICROB AGENTS CH, V52, P2383, DOI 10.1128-AAC.01641-07; Draghi DC, 2008, J ANTIMICROB CHEMOTH, V62, P116, DOI 10.1093-jac-dkn124; File TM, 2010, CLIN INFECT DIS, V51, P1395, DOI 10.1086-657313; Freire AT, 2010, DIAGN MICR INFEC DIS, V68, P140, DOI 10.1016-j.diagmicrobio.2010.05.012; Gander S, 2005, J ANTIMICROB CHEMOTH, V56, P337, DOI 10.1093-jac-dki198; Georges H, 1997, EUR J CLIN MICROBIOL, V16, P385, DOI 10.1007-BF01726369; Goldberg MR, 2010, PHARMACOTHERAPY, V30, P35, DOI 10.1592-phco.30.1.35; Goldberg MR, 2010, PHARMACOTHERAPY, V30, P806, DOI 10.1592-phco.30.8.806; Goldstein EJC, 2004, ANTIMICROB AGENTS CH, V48, P2149, DOI 10.1128-ACC.48.6.2149-2152.2004; Gonzalez C, 1999, CLIN INFECT DIS, V29, P1171, DOI 10.1086-313440; Gotfried MH, 2008, ANTIMICROB AGENTS CH, V52, P92, DOI 10.1128-AAC.00875-07; Gradelski E, 2001, INT J ANTIMICROB AG, V18, P43, DOI 10.1016-S0924-8579(01)00343-0; Hatano K, 2007, J ANTIBIOT, V60, P709; Hegde SS, 2004, ANTIMICROB AGENTS CH, V48, P3043, DOI 10.1128-AAC.48.8.3043-3050.2004; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249; Hidayat LK, 2006, ARCH INTERN MED, V166, P2138, DOI 10.1001-archinte.166.19.2138; Higgins DL, 2005, ANTIMICROB AGENTS CH, V49, P1127, DOI 10.1128-AAC.49.3.1127-1134.2005; Honeybourne D, 2003, J ANTIMICROB CHEMOTH, V51, P1431, DOI 10.1093-jac-dkg262; Kalil AC, 2010, CRIT CARE MED, V38, P1802, DOI 10.1097-CCM.0b013e3181eb3b96; Kiem S, 2008, ANTIMICROB AGENTS CH, V52, P24, DOI 10.1128-AAC.00133-06; King A, 2004, J ANTIMICROB CHEMOTH, V53, P797, DOI 10.1093-jac-dkh156; Klevens RM, 2006, CLIN INFECT DIS, V42, P389, DOI 10.1086-499367; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378-chest.113.2.412; Kollef MH, 2005, CHEST, V128, P3854, DOI 10.1378-chest.128.6.3854; KUNKEL M, 2010, INF DIS SOC AM 48 AN; LAMER C, 1993, ANTIMICROB AGENTS CH, V37, P281; Leadbetter MR, 2004, J ANTIBIOT, V57, P326; Leonard SN, 2008, PHARMACOTHERAPY, V28, P458, DOI 10.1592-phco.28.4.458; Leuthner KD, 2006, J ANTIMICROB CHEMOTH, V58, P338, DOI 10.1093-jac-dkl235; Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086-491709; Liu C, 2011, CLIN INFECT DIS, V52, pE18, DOI 10.1093-cid-ciq146; Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P3315, DOI 10.1128-AAC.00113-08; Lodise TP, 2007, ANTIMICROB AGENTS CH, V51, P3731, DOI 10.1128-AAC.00101-07; Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P2300, DOI 10.1128-AAC.01110-07; Lodise TP, 2009, CLIN INFECT DIS, V49, P507, DOI 10.1086-600884; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378-chest.111.3.676; Lunde CS, 2009, ANTIMICROB AGENTS CH, V53, P3375, DOI 10.1128-AAC.01710-08; Madrigal AG, 2005, ANTIMICROB AGENTS CH, V49, P3163, DOI 10.1128-AAC.49.8.3163-3165.2005; Mendes RE, 2010, INT J ANTIMICROB AG, V36, P374, DOI 10.1016-j.ijantimicag.2010.05.016; Mimoz O, 2006, INTENS CARE MED, V32, P775, DOI 10.1007-s00134-006-0136-3; Nannini EC, 2008, EXPERT OPIN PHARMACO, V9, P2197, DOI 10.1517-14656566.9.12.2197 ; Nguyen HA, 2009, ANTIMICROB AGENTS CH, V53, P1434, DOI 10.1128-AAC.01145-08; Odenholt I, 2007, ANTIMICROB AGENTS CH, V51, P3311, DOI 10.1128-AAC.01470-06; Pace JL, 2003, ANTIMICROB AGENTS CH, V47, P3602, DOI 10.1128-AAC.47.11.3602-3604.2003; Pertel PE, 2008, CLIN INFECT DIS, V46, P1142, DOI 10.1086-533441; Pfaller MA, 2010, J ANTIMICROB CHEMOTH, V65, P2396, DOI 10.1093-jac-dkq335; *PFIZ INC, 2010, ZYVOX LIN INJ LIN TA; Powers JH, 2004, CHEST, V126, P314, DOI 10.1378-chest.126.1.314; Putnam SD, 2010, DIAGN MICR INFEC DIS, V67, P359, DOI 10.1016-j.diagmicrobio.2010.03.009; Reyes N, 2006, J ANTIMICROB CHEMOTH, V58, P462, DOI 10.1093-jac-dkl222; Reyes N, 2005, ANTIMICROB AGENTS CH, V49, P4344, DOI 10.1128-AAC.49.10.4344-4346.2005; Rodvold KA, 2009, ANTIMICROB AGENTS CH, V53, P3294, DOI 10.1128-AAC.00144-09; Rotstein C, 2008, CAN J INFECT DIS MED, V19, P19; Rubinstein E, 2011, CLIN INFECT DIS, V52, P31, DOI 10.1093-cid-ciq031; Rybak MJ, 2006, CLIN INFECT DIS, V42, pS35, DOI 10.1086-491712; Sader HS, 2009, ANTIMICROB AGENTS CH, V53, P4127, DOI 10.1128-AAC.00616-09; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097-01.CCM.0000181731.53912.D9; Saravolatz LD, 2007, J ANTIMICROB CHEMOTH, V60, P406, DOI 10.1093-jac-dkm211; Shaw JP, 2010, ANTIMICROB AGENTS CH, V54, P3365, DOI 10.1128-AAC.01750-09; Shaw JP, 2005, ANTIMICROB AGENTS CH, V49, P195, DOI 10.1128-AAC.49.1.195-201.2005; Silverman JA, 2005, J INFECT DIS, V191, P2149, DOI 10.1086-430352; Sivagnanam S, 2003, CRIT CARE, V7, P119, DOI 10.1186-cc1871; Soriano A, 2008, CLIN INFECT DIS, V46, P193, DOI 10.1086-524667; Steinkraus G, 2007, J ANTIMICROB CHEMOTH, V60, P788, DOI 10.1093-jac-dkm258; Stryjewski ME, 2006, ANTIMICROB AGENTS CH, V50, P862, DOI 10.1128-AAC.50.3.862-867.2006; Stryjewski ME, 2007, CLIN INFECT DIS, V44, P190, DOI 10.1086-510386; Stryjewski ME, 2008, CLIN INFECT DIS, V46, P1683, DOI 10.1086-587896; Stryjewski ME, 2005, CLIN INFECT DIS, V40, P1601, DOI 10.1086-429914; Stucki A, 2006, ANTIMICROB AGENTS CH, V50, P770, DOI 10.1128-AAC.50.2.770-773.2006; Sun HK, 2006, ANTIMICROB AGENTS CH, V50, P788, DOI 10.1128-AAC.50.2.788-790.2006; Tice AD, 2003, J ANTIMICROB CHEMOTH, V51, P1261, DOI 10.1093-jac-dkg186; Torres A, 2009, INTENS CARE MED, V35, P9, DOI 10.1007-s00134-008-1336-9; Tsuji BT, 2008, DIAGN MICR INFEC DIS, V60, P441, DOI 10.1016-j.diagmicrobio.2007.11.011; Wang GQ, 2006, J CLIN MICROBIOL, V44, P3883, DOI 10.1128-JCM.01388-06; Wong SL, 2010, PHARMACOTHERAPY, V30, P136, DOI 10.1592-phco.30.2.136; Wunderink RG, 2003, CHEST, V124, P1789, DOI 10.1378-chest.124.5.1789; *WYETH PHARM INC, 2010, TYGACIL TIG FOR INJ; 2009, DA 22 110 VIBATIV TE55
Mining e-mail content for author identification forensics
No full textWe describe an investigation into e-mail content mining for author identification, or authorship attribution, for the purpose of forensic investigation. We focus our discussion on the ability to discriminate between authors for the case of both aggregated e-mail topics as well as across different email topics. An extended set of e-mail document features including structural characteristics and linguistic patterns were derived and, together with a Support Vector Machine learning algorithm, were used for mining the e-mail content. Experiments using a number of e-mail documents generated by different authors on a set of topics gave promising results for both aggregated and multi-topic author categorisation
Dispelling the Myths Behind First-author Citation Counts
No full textWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
"Reflections on the subject of Emigration from Europe with a view to Settlement in the United States" By M. Carey.
No full text"Reflections on the subject of Emigration from Europe with a view to Settlement in the United States: containing bried sketches of the moral and political character of those states.
By M. Carey, member of the American philosophical, and of the American Antiquarian Society, and author of The Olive Branch, Cindiciae Hibernicae, essays on banking, on political economy, and on internal improvement.
To which are now added the English editor's comments on the subject; together with Important Advice to Emigrants, and Cautions Against Impositions Practiced in the Outports
Author, publisher and bookseller : a tripartite synergy in Nigerian book industry
No full textThis work is about the roles of Author, Publisher and Bookseller in Book development in
Nigeria. The paper started by delving into the history of Book Publishing in Nigeria after
which it proceeded by defining who an author, a publisher, and a bookseller is and
expatiated on the indispensable roles of these key actors in Nigerian Book Industry and in
the emerging Information Society. Furthermore, the various constraints to book
development were identified while the paper advised on how the Book Industry can be
further promoted in Nigeria. However, the paper concluded and made recommendations
on how the Book sector can help in enhancing scholarship in the country
The long-wavelength view of GG Tau A: rocks in the ring world
No full textWe present the first detection of GG Tau A at centimetre wavelengths, made with the Arcminute Microkelvin Imager Large Array at a frequency of 16 GHz (λ = 1.8 cm). The source is detected at >6 σrms with an integrated flux density of S16GHz = 249 ± 45 µJy. We use these new centimetre-wave data, in conjunction with additional measurements compiled from the literature, to investigate the long-wavelength tail of the dust emission from this unusual protoplanetary system. We use an MCMC-based method to determine maximum likelihood parameters for a simple parametric spectral model and consider the opacity and mass of the dust contributing to the microwave emission. We derive a dust mass of Md ~ 0.1 Msun, constrain the dimensions of the emitting region and find that the opacity index at λ > 7 mm is less than unity, implying a contribution to the dust population from grains exceeding ~4 cm in size. We suggest that this indicates coagulation within the GG Tau A system has proceeded to the point where dust grains have grown to the size of small rocks with dimensions of a few centimetres. Considering the relatively young age of the GG Tau association in combination with the low derived disc mass, we suggest that this system may provide a useful test case for rapid core accretion planet formation models
Simulation of thermal plant optimization and hydraulic aspects of thermal distribution loops for large campuses
No full textFollowing an introduction, the author describes Texas A&M University and its utilities system. After that, the author presents how to construct simulation models for chilled water and heating hot water distribution systems. The simulation model was used in a $2.3 million Ross Street chilled water pipe replacement project at Texas A&M University. A second project conducted at the University of Texas at San Antonio was used as an example to demonstrate how to identify and design an optimal distribution system by using a simulation model. The author found that the minor losses of these closed loop thermal distribution systems are significantly higher than potable water distribution systems. In the second part of the report, the author presents the latest development of software called the Plant Optimization Program, which can simulate cogeneration plant operation, estimate its operation cost and provide optimized operation suggestions. The author also developed detailed simulation models for a gas turbine and heat recovery steam generator and identified significant potential savings. Finally, the author also used a steam turbine as an example to present a multi-regression method on constructing simulation models by using basic statistics and optimization algorithms. This report presents a survey of the author??s working experience at the Energy Systems Laboratory (ESL) at Texas A&M University during the period of January 2002 through March 2004. The purpose of the above work was to allow the author to become familiar with the practice of engineering. The result is that the author knows how to complete a project from start to finish and understands how both technical and nontechnical aspects of a project need to be considered in order to ensure a quality deliverable and bring a project to successful completion. This report concludes that the objectives of the internship were successfully accomplished and that the requirements for the degree of Degree of Engineering have been satisfied
- …
